Replimune Group, Inc. REPL announced that the FDA has accepted the biologics license application (BLA) for its lead pipeline ...

Replimune Group (NASDAQ:REPL – Get Free Report) had its price target raised by investment analysts at BMO Capital Markets ...

The Ohio Department of Commerce received reports of unsolicited offers for properties across the state. Here's what to do if it happens to you.

Replimune Group, Inc. (NASDAQ:REPL – Get Free Report) has been given a consensus rating of “Buy” by the eight research firms that are currently covering the firm, Ratings reports. Seven research ...

(RTTNews) - Replimune Group, Inc. (REPL), Tuesday announced that the U.S. Food and Drug Administration has accepted the Biologics License Application for RP1 in combination with Nivolumab for the ...

Group announced that the U.S. Food and Drug Administration, FDA, has accepted the Biologics License Application, BLA, for RP1 ...

PDUFA action date of July 22, 2025, with priority reviewWOBURN, Mass., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the ...

Charles Schwab Posts Upbeat Earnings, Joins Redwire, Evolus, Replimune Group And Other Big Stocks Moving Higher On Tuesday ...